TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial) | Zendy

Nadine Tung | Zendy; Banu K. Arun | Zendy; Michele R. Hacker | Zendy; Erin Hofstatter | Zendy; Deborah Toppmeyer | Zendy; Steven J. Isakoff | Zendy; Virginia F. Borges | Zendy; Robert D. Legare | Zendy; Claudine Isaacs | Zendy; Antonio C. Wolff | Zendy; P. Kelly Marcom | Zendy; Erica L. Mayer | Zendy; Paulina Lange | Zendy; Andrew J. Goss | Zendy; C. David Jenkins | Zendy; Ian E. Krop | Zendy; Eric P. Winer | Zendy; Stuart J. Schnitt | Zendy; Judy E. Garber | Zendy

Open Access

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

Author(s) -

Nadine Tung,

Banu K. Arun,

Michele R. Hacker,

Erin Hofstatter,

Deborah Toppmeyer,

Steven J. Isakoff,

Virginia F. Borges,

Robert D. Legare,

Claudine Isaacs,

Antonio C. Wolff,

P. Kelly Marcom,

Erica L. Mayer,

Paulina Lange,

Andrew J. Goss,

C. David Jenkins,

Ian E. Krop,

Eric P. Winer,

Stuart J. Schnitt,

Judy E. Garber

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.03292

Subject(s) - medicine , breast cancer , cyclophosphamide , oncology , brca mutation , triple negative breast cancer , cancer , chemotherapy , doxorubicin

Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers ( BRCA carriers). Limited data exist for estrogen receptor (ER)-positive (+) breast cancer among BRCA carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorubicin-cyclophosphamide (AC) in BRCA carriers with stage I-III human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Secondary objectives included residual cancer burden scores (RCB) of 0 or 1 (combined) and toxicity. The goal was to determine whether pCR was ≥ 20% higher with CDDP than AC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research